Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Sell
41
QNTM Quote, Financials, Valuation and Earnings
Last price:
$22.40
Seasonality move
:
27.9%
Day range:
$19.11 - $22.50
52-week range:
$2.70 - $38.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
13.41x
Volume:
195.4K
Avg. volume:
337.4K
1-year change:
133.48%
Market cap:
$76.9M
Revenue:
--
EPS (TTM):
-$15.23
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Quantum BioPharma has 2931.08% upside to fair value with a price target of -- per share.
QNTM vs. S&P 500
-
Over the past 5 trading days, Quantum BioPharma has overperformed the S&P 500 by 33.21% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Quantum BioPharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Quantum BioPharma has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Quantum BioPharma reported revenues of --.
Earnings Growth
-
Quantum BioPharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Quantum BioPharma reported earnings per share of -$3.53.
Enterprise value:
73.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$30.6M | -$12.5M | -$17M | -$2.3M | -$3.4M | |
| EBITDA | -$26.6M | -$10.5M | -$20.7M | -$2M | -$8.3M | |
| Diluted EPS | -$47.41 | -$17.16 | -$15.23 | -$3.43 | -$3.53 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $60.8M | $39.6M | $10.7M | $9.2M | $9.9M | |
| Total Assets | $76.4M | $55.7M | $29.5M | $15.4M | $14.9M | |
| Current Liabilities | $7.9M | $8.9M | $8.6M | $3.9M | $10.3M | |
| Total Liabilities | $7.9M | $8.9M | $8.6M | $3.9M | $10.3M | |
| Total Equity | $68.5M | $46.8M | $20.9M | $11.5M | $4.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28M | -$8M | -$9.2M | -$2M | -$4.3M | |
| Cash From Investing | $12.2M | -$291.7K | -$2.8M | -$22.1K | -$1.4M | |
| Cash From Financing | -$3.6M | $445.6K | $14.2M | $568.7K | $3.1M | |
| Free Cash Flow | -$28M | -$8M | -$9.2M | -$2M | -$4.3M | |
QNTM
Sector
Market Cap
$76.9M
$34.4M
Price % of 52-Week High
58.72%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
133.48%
-37.36%
Beta (5-Year)
0.675
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$18.90
200-day SMA
Buy
Level
$8.15
Bollinger Bands (100)
Buy
Level
4.63 - 17.87
Chaikin Money Flow
Buy
Level
523.7K
20-day SMA
Buy
Level
$21.76
Relative Strength Index (RSI14)
Buy
Level
56.94
ADX Line
Buy
Level
32.3
Williams %R
Neutral
Level
-21.9917
50-day SMA
Buy
Level
$16.26
MACD (12, 26)
Buy
Level
5.51
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
483.2K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Stock Forecast FAQ
In the current month, QNTM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The QNTM average analyst price target in the past 3 months is --.
-
Where Will Quantum BioPharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Quantum BioPharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Quantum BioPharma?
Analysts are divided on their view about Quantum BioPharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Quantum BioPharma is a Sell and believe this share price will drop from its current level to --.
-
What Is Quantum BioPharma's Price Target?
The price target for Quantum BioPharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is QNTM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Quantum BioPharma is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of QNTM?
You can purchase shares of Quantum BioPharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Quantum BioPharma shares.
-
What Is The Quantum BioPharma Share Price Today?
Quantum BioPharma was last trading at $22.40 per share. This represents the most recent stock quote for Quantum BioPharma. Yesterday, Quantum BioPharma closed at $22.46 per share.
-
How To Buy Quantum BioPharma Stock Online?
In order to purchase Quantum BioPharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is up 0.32% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 0.39% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 11.7% over the past day.
